Suraj Sarvode Mothi1, Neeraj Tandon2, Jaya Padmanabhan3, Ian T Mathew3, Brett Clementz4, Carol Tamminga5, Godfrey Pearlson6, John Sweeney7, Matcheri S Keshavan8. 1. Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Psychiatry, Harvard Medical School-Beth Israel Deaconess Medical Center, Boston, MA, USA. 2. Psychiatry, Harvard Medical School-Beth Israel Deaconess Medical Center, Boston, MA, USA; Baylor College of Medicine, Texas Medical Center, Houston, TX, USA. 3. Psychiatry, Harvard Medical School-Beth Israel Deaconess Medical Center, Boston, MA, USA. 4. Department of Psychology, Bio-Imaging Research Center, University of Georgia, Athens, GA, USA; Department of Neuroscience, Bio-Imaging Research Center, University of Georgia, Athens, GA, USA. 5. Psychiatry, UT Southwestern, Dallas, TX, USA. 6. Olin Neuropsychiatry Research Center, Hartford, CT, USA; Department of Psychiatry and Neurobiology, Yale University, New Haven, CT, USA. 7. Department of Neuroscience, Bio-Imaging Research Center, University of Georgia, Athens, GA, USA. 8. Psychiatry, Massachusetts General Hospital, Boston, MA, USA. Electronic address: mkeshava@bidmc.harvard.edu.
Abstract
INTRODUCTION: Elevated prevalence of comorbid cardio-vascular and metabolic dysfunction (CMD) is consistently reported in patients with severe psychotic disorders such as schizophrenia (SZ), schizoaffective (SZA) and bipolar disorder (BP-P). Since both psychosis and CMD are substantively heritable in nature, we attempted to investigate the occurrence of CMD disorders in first-degree relatives of probands with psychosis. METHODS: Our sample included 861 probands with a diagnosis of SZ (n=354), SZA (n=212) and BP-P (n=295), 776 first-degree relatives of probands and 416 healthy controls. Logistic regression was used to compare prevalence of any CMD disorders (diabetes, hypertension, hyperlipidemia or coronary artery disease) across groups. Post hoc tests of independence checked for CMD prevalence across psychosis diagnosis (SZ, SZA and BP-P), both in relatives of probands and within probands themselves. RESULTS: After controlling for potential confounders, first-degree relatives with (p<0.001) and without (p=0.03) Axis I non-psychotic or Axis- II cluster disorders were at a significant risk for CMD compared to controls. No significant difference (p=0.42) was observed in prevalence of CMD between relatives of SZ, SZA and BP-P, or between psychosis diagnoses for probands (p=0.25). DISCUSSION: Prevalence of CMD was increased in the first-degree relatives of psychosis subjects. This finding suggests the possibility of overlapping genetic contributions to CMD and psychosis. Increased somatic disease burden in relatives of psychotic disorder probands points to need for early detection and preventive efforts in this population.
INTRODUCTION: Elevated prevalence of comorbid cardio-vascular and metabolic dysfunction (CMD) is consistently reported in patients with severe psychotic disorders such as schizophrenia (SZ), schizoaffective (SZA) and bipolar disorder (BP-P). Since both psychosis and CMD are substantively heritable in nature, we attempted to investigate the occurrence of CMD disorders in first-degree relatives of probands with psychosis. METHODS: Our sample included 861 probands with a diagnosis of SZ (n=354), SZA (n=212) and BP-P (n=295), 776 first-degree relatives of probands and 416 healthy controls. Logistic regression was used to compare prevalence of any CMD disorders (diabetes, hypertension, hyperlipidemia or coronary artery disease) across groups. Post hoc tests of independence checked for CMD prevalence across psychosis diagnosis (SZ, SZA and BP-P), both in relatives of probands and within probands themselves. RESULTS: After controlling for potential confounders, first-degree relatives with (p<0.001) and without (p=0.03) Axis I non-psychotic or Axis- II cluster disorders were at a significant risk for CMD compared to controls. No significant difference (p=0.42) was observed in prevalence of CMD between relatives of SZ, SZA and BP-P, or between psychosis diagnoses for probands (p=0.25). DISCUSSION: Prevalence of CMD was increased in the first-degree relatives of psychosis subjects. This finding suggests the possibility of overlapping genetic contributions to CMD and psychosis. Increased somatic disease burden in relatives of psychotic disorder probands points to need for early detection and preventive efforts in this population.
Authors: Sanjat Kanjilal; Edward W Gregg; Yiling J Cheng; Ping Zhang; David E Nelson; George Mensah; Gloria L A Beckles Journal: Arch Intern Med Date: 2006-11-27
Authors: Alfredo J Selim; Graeme Fincke; Xinhua S Ren; Austin Lee; William H Rogers; Donald R Miller; Katherine M Skinner; Mark Linzer; Lewis E Kazis Journal: J Ambul Care Manage Date: 2004 Jul-Sep
Authors: Carol A Tamminga; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Brett A Clementz; Bradley Witte; David W Morris; Jeffrey Bishop; Gunvant K Thaker; John A Sweeney Journal: Am J Psychiatry Date: 2013-11 Impact factor: 18.112
Authors: David P J Osborn; Christine A Wright; Gus Levy; Michael B King; Raman Deo; Irwin Nazareth Journal: BMC Psychiatry Date: 2008-09-25 Impact factor: 3.630
Authors: Rodrigo B Mansur; Gabriel R Fries; Mehala Subramaniapillai; Sophia Frangou; Fernanda G De Felice; Natalie Rasgon; Bruce McEwen; Elisa Brietzke; Roger S McIntyre Journal: J Psychiatr Res Date: 2018-10-27 Impact factor: 4.791
Authors: Jaya L Padmanabhan; Pranav Nanda; Neeraj Tandon; Suraj S Mothi; Nicolas Bolo; Steven McCarroll; Brett A Clementz; Elliot S Gershon; Godfrey D Pearlson; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan Journal: J Psychiatr Res Date: 2016-02-23 Impact factor: 4.791
Authors: M Ikeda; A Takahashi; Y Kamatani; Y Okahisa; H Kunugi; N Mori; T Sasaki; T Ohmori; Y Okamoto; H Kawasaki; S Shimodera; T Kato; H Yoneda; R Yoshimura; M Iyo; K Matsuda; M Akiyama; K Ashikawa; K Kashiwase; K Tokunaga; K Kondo; T Saito; A Shimasaki; K Kawase; T Kitajima; K Matsuo; M Itokawa; T Someya; T Inada; R Hashimoto; T Inoue; K Akiyama; H Tanii; H Arai; S Kanba; N Ozaki; I Kusumi; T Yoshikawa; M Kubo; N Iwata Journal: Mol Psychiatry Date: 2017-01-24 Impact factor: 15.992